Showing results (661-670 of 784) with videos related to

Sort By:
Pageof 79
BMC Musculoskeletal Disorders|December 26, 2014
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugNuria C Navarro Coy, Sarah Brown, Ailsa Bosworth, et al.
Bioorganic & Medicinal Chemistry|February 5, 2000
Model studies on a synthetically facile series of N-substituted phenyl-N'-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT(2C/2B) receptor antagonistsS M Bromidge, S Dabbs, D T Davies, et al.
Chemical Science|April 6, 2018
Unequivocal determination of caulamidines A and B: application and validation of new tools in the structure elucidation tool boxDennis J Milanowski, Naoya Oku, Laura K Cartner, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Virtual Screening Approach to Identifying a Novel and Tractable Series of <i>Pseudomonas aeruginosa</i> Elastase InhibitorsSimon Leiris, David T Davies, Nicolas Sprynski, et al.
Bioorganic & Medicinal Chemistry Letters|November 30, 2013
Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZNeil R Stokes, Nicola Baker, James M Bennett, et al.
The Journal of Craniofacial Surgery|July 14, 2021
Surgical Site Infection After Autologous Cranioplasty for Decompressive Craniectomy in Traumatic Brain Injury: A Retrospective Review of Two Level 1 Trauma CentersJames P Caruso, Samuel Griffin, Tarek Y El Ahmadieh, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerasesTimothy J Miles, Alan J Hennessy, Ben Bax, et al.
Bioorganic & Medicinal Chemistry Letters|November 4, 2011
Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerasesTimothy J Miles, Jeffrey M Axten, Christopher Barfoot, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2026
CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitinationRuhi Polara, Briony L Gliddon, Raja Ganesan, et al.
Journal of Medicinal Chemistry|May 30, 1998
Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolinesS M Bromidge, S Dabbs, D T Davies, et al.
Pageof 79